Advertisement

PharmacoEconomics & Outcomes News

, Volume 527, Issue 1, pp 4–4 | Cite as

Trastuzumab cost effective in HER2-positive breast cancer

News item

Keywords

Trastuzumab Early Breast Cancer Incremental Cost Effectiveness Ratio Adjuvant Trastuzumab Positive Early Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

REFERENCE

  1. 1.
    Liberato NL, Marchetti M, Barosi G.Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology 25: 625-633, No. 6, 20 Feb 2007Google Scholar
  2. 2.
    Kurian AW, Newton Thompson R, Gaw AF, Arai S, Ortiz R, Garber AM.A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. Journal of Clinical Oncology 25: 634-641, No. 6, 20 Feb 2007Google Scholar
  3. 3.
    Hillner BE, Smith TJ.Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? Journal of Clinical Oncology 25: 611-613, No. 6, 20 Feb 2007Google Scholar

Copyright information

© Adis International Ltd 2007

Personalised recommendations